Tango Therapeutics Inc. (TNGX) PT Raised to $40 at Stifel on Higher PRMT5 Inhibitor Conviction
Stifel analyst Laura Prendergast raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $40.00 (from $24.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)